Generation of humanized anti-CD3 producing cell lines and recombinant antigen expression

Abstract

Anti-CD3 monoclonal antibodies (mAbs) produced by hybridomas were initially used for transplant rejection treatment. Due to its potential ability to induce immune tolerance, attempts were made to use these mAbs by other therapeutic areas, such as autoimmune diseases control. However, most of anti-CD3 mAb were murine derivatives and highly immunogenic in humans, which hampered its broader usage. The recombinant mAb technology has revolutionized the biopharmaceuticals field by producing humanized antibodies directed to specific antigens. Therefore, minimizing immunogenicity and toxicity induced by anti-CD3 treatment, as well as the generation of stable and highly productive mAb cell lines, are of special interest for anti-CD3 therapy. This work proposes different strategies to find the best conditions for a humanized anti-CD3 cell line generation, producing antibody for use in functional in vitro and in vivo testing. In addition, we intend to express the CD3 antigen in order to replace human lymphocytes in analytical assays. (AU)